MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
The original release is unavailable here.
Earlier from Metavia
- MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
- MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
- MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
- MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity